This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Why Akebia Therapeutics (AKBA) Stock Soared Today

Stock quotes in this article: AKBA

NEW YORK (TheStreet) -- Akebia Therapeutics (AKBA) soared more than 25% on Monday on high volume after UBS initiated coverage on the biopharmaceutical company with a "buy" rating and $28 price target.

"Akebia Therapeutics is a clinical-stage biotech company that we believe is well positioned to produce a treatment for anemia that is potentially safer than current products, which have black box warnings for increased death and cardiovascular events but generated >$6bn in sales in 2013," UBS wrote in a research note. "The company's wholly-owned once-daily oral HIF-PH inhibitor AKB-6548 is in Phase-2b for anemia of chronic kidney disease (CKD). Akebia's second candidate, AKB-6899, is in preclinical studies for oncology."

The Cambridge, Mass.-based drug maker went public in March. UBS also outlined the following points to support its "buy" rating:

[1] HIF activators could become the standard of care in the anemia market if they are approved without the same black box warnings as injectable erythropoiesis-stimulating agents (ESAs) and hence are perceived to be safer than ESAs. The safety of AKB-6548 is supported by clinical and pre-clinical data and the highaltitude literature, which shows no untoward effect of HIF activation. [2] We see blockbuster potential for '6548 if it is found to be safe and effective. It would be second to market but would be well-positioned among competitors due to attractive once-daily dosing and still be ahead of two additional competitors in a multi-billion dollar market. [3] Near term ph2b data (4Q14e) could drive a valuation step-up in AKBA shares. [4] Management has extensive knowledge and experience executing in the CKD segment.

The stock closed up 25.39% to $21.14, a $4.28 increase from its previous close of $16.86. More than 2.9 million hares changed hands, well above the average volume of 423,041. The stock held a range of $17.07 to $23.32 for the day and holds a one-year range of $16.41 to $28.50.

Must Read: Warren Buffett's 10 Favorite Growth Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. AKBA Chart

AKBA data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,878.98 -163.92 -0.96%
S&P 500 1,958.86 -13.43 -0.68%
NASDAQ 4,449.3440 -44.0460 -0.98%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs